Human Genomics,
Journal Year:
2019,
Volume and Issue:
13(1)
Published: Aug. 1, 2019
In
recent
years,
the
rapid
development
of
next-generation
sequencing
(NGS)
technologies
has
led
to
a
significant
reduction
in
cost
with
improved
accuracy.
area
liquid
biopsy,
NGS
been
applied
sequence
circulating
tumor
DNA
(ctDNA).
Since
ctDNA
is
fragments
released
by
cells,
it
can
provide
molecular
profile
cancer.
Liquid
biopsy
be
all
stages
cancer
diagnosis
and
treatment,
allowing
non-invasive
real-time
monitoring
disease
development.
The
most
promising
aspects
applications
are
screening
early
because
they
lead
better
survival
results
less
burden.
Although
many
methods
have
enough
sensitivity
detect
extremely
low
levels
mutation
frequency
at
stage
cancer,
how
effectively
implement
them
population
settings
remains
challenging.
This
paper
focuses
on
application
introduces
NGS-related
methods,
reviews
progress,
summarizes
challenges,
discusses
future
research
directions.
New England Journal of Medicine,
Journal Year:
2016,
Volume and Issue:
376(7), P. 629 - 640
Published: Dec. 6, 2016
Osimertinib
is
an
epidermal
growth
factor
receptor
tyrosine
kinase
inhibitor
(EGFR-TKI)
that
selective
for
both
EGFR-TKI
sensitizing
and
T790M
resistance
mutations
in
patients
with
non-small-cell
lung
cancer.
The
efficacy
of
osimertinib
as
compared
platinum-based
therapy
plus
pemetrexed
such
unknown.
Journal of the National Comprehensive Cancer Network,
Journal Year:
2017,
Volume and Issue:
15(4), P. 504 - 535
Published: April 1, 2017
This
selection
from
the
NCCN
Guidelines
for
Non–Small
Cell
Lung
Cancer
(NSCLC)
focuses
on
targeted
therapies
and
immunotherapies
metastatic
NSCLC,
because
therapeutic
recommendations
are
rapidly
changing
disease.
For
example,
new
were
added
atezolizumab,
ceritinib,
osimertinib,
pembrolizumab
2017
updates.
Journal of the National Comprehensive Cancer Network,
Journal Year:
2022,
Volume and Issue:
20(5), P. 497 - 530
Published: May 1, 2022
NCCN
Clinical
Practice
Guidelines
in
Oncology
(NCCN
Guidelines)
for
Non-Small
Cell
Lung
Cancer
(NSCLC)
provide
recommended
management
patients
with
NSCLC,
including
diagnosis,
primary
treatment,
surveillance
relapse,
and
subsequent
treatment.
Patients
metastatic
lung
cancer
who
are
eligible
targeted
therapies
or
immunotherapies
now
surviving
longer.
This
selection
from
the
NSCLC
focuses
on
actionable
mutations.
British Journal of Cancer,
Journal Year:
2019,
Volume and Issue:
121(9), P. 725 - 737
Published: Sept. 29, 2019
Abstract
Osimertinib
is
an
irreversible,
third-generation
epidermal
growth
factor
receptor
(EGFR)
tyrosine
kinase
inhibitor
that
highly
selective
for
EGFR-
activating
mutations
as
well
the
EGFR
T790M
mutation
in
patients
with
advanced
non-small
cell
lung
cancer
(NSCLC)
oncogene
addiction.
Despite
documented
efficacy
of
osimertinib
first-
and
second-line
settings,
inevitably
develop
resistance,
no
further
clear-cut
therapeutic
options
to
date
other
than
chemotherapy
locally
ablative
therapy
selected
individuals.
On
account
high
degree
tumour
heterogeneity
adaptive
cellular
signalling
pathways
NSCLC,
acquired
resistance
heterogeneous,
encompassing
-
dependent
EGFR-independent
mechanisms.
Furthermore,
data
from
repeat
plasma
genotyping
analyses
have
highlighted
differences
frequency
preponderance
mechanisms
when
administered
a
front-line
versus
setting,
underlying
discrepancies
selection
pressure
clonal
evolution.
This
review
summarises
molecular
mutated
including
MET/HER2
amplification,
activation
RAS–mitogen-activated
protein
(MAPK)
or
RAS–phosphatidylinositol
3-kinase
(PI3K)
pathways,
novel
fusion
events
histological/phenotypic
transformation,
discussing
current
evidence
regarding
potential
new
approaches
counteract
resistance.
